124 related articles for article (PubMed ID: 17201419)
1. Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors.
Lee YS; Agnes RS; Davis P; Ma SW; Badghisi H; Lai J; Porreca F; Hruby VJ
J Med Chem; 2007 Jan; 50(1):165-8. PubMed ID: 17201419
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
Lee YS; Agnes RS; Badghisi H; Davis P; Ma SW; Lai J; Porreca F; Hruby VJ
J Med Chem; 2006 Mar; 49(5):1773-80. PubMed ID: 16509592
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Agnes RS; Lee YS; Davis P; Ma SW; Badghisi H; Porreca F; Lai J; Hruby VJ
J Med Chem; 2006 May; 49(10):2868-75. PubMed ID: 16686530
[TBL] [Abstract][Full Text] [Related]
4. Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain.
Hruby VJ; Agnes RS; Davis P; Ma SW; Lee YS; Vanderah TW; Lai J; Porreca F
Life Sci; 2003 Jun; 73(6):699-704. PubMed ID: 12801591
[TBL] [Abstract][Full Text] [Related]
5. A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
Yamamoto T; Nair P; Vagner J; Largent-Milnes T; Davis P; Ma SW; Navratilova E; Moye S; Tumati S; Lai J; Yamamura HI; Vanderah TW; Porreca F; Hruby VJ
J Med Chem; 2008 Mar; 51(5):1369-76. PubMed ID: 18266313
[TBL] [Abstract][Full Text] [Related]
6. Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
McDonald IM; Austin C; Buck IM; Dunstone DJ; Griffin E; Harper EA; Hull RA; Kalindjian SB; Linney ID; Low CM; Pether MJ; Spencer J; Wright PT; Adatia T; Bashall A
J Med Chem; 2006 Apr; 49(7):2253-61. PubMed ID: 16570921
[TBL] [Abstract][Full Text] [Related]
7. Conformationally readdressed CCK-B/delta-opioid peptide ligands.
Nikiforovich GV; Kolodziej SA; Nock B; Bernad N; Martinez J; Marshall GR
Biopolymers; 1995 Oct; 36(4):439-52. PubMed ID: 7578939
[TBL] [Abstract][Full Text] [Related]
8. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of bifunctional cyclic disulfide peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Agnes RS; Ying J; Kövér KE; Lee YS; Davis P; Ma SW; Badghisi H; Porreca F; Lai J; Hruby VJ
Peptides; 2008 Aug; 29(8):1413-23. PubMed ID: 18502541
[TBL] [Abstract][Full Text] [Related]
10. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
11. SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptors.
Williams CL; Rosenfeld GC; Dafny N; Fang SN; Hruby VJ; Bowden G; Cullinan CA; Burks TF
J Pharmacol Exp Ther; 1994 May; 269(2):750-5. PubMed ID: 8182541
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
[TBL] [Abstract][Full Text] [Related]
13. Estrogen and CCK1 receptor modification of mu-opioid receptor binding in the cortex of female rats.
Quesada A; Micevych P
Brain Res; 2006 Feb; 1073-1074():316-20. PubMed ID: 16472782
[TBL] [Abstract][Full Text] [Related]
14. Association of enkephalin catabolism inhibitors and CCK-B antagonists: a potential use in the management of pain and opioid addiction.
Roques BP; Noble F
Neurochem Res; 1996 Nov; 21(11):1397-410. PubMed ID: 8947930
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2007 May; 50(9):2254-8. PubMed ID: 17407276
[TBL] [Abstract][Full Text] [Related]
16. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW
J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087
[TBL] [Abstract][Full Text] [Related]
17. Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain.
Hanlon KE; Herman DS; Agnes RS; Largent-Milnes TM; Kumarasinghe IR; Ma SW; Guo W; Lee YS; Ossipov MH; Hruby VJ; Lai J; Porreca F; Vanderah TW
Brain Res; 2011 Jun; 1395():1-11. PubMed ID: 21550594
[TBL] [Abstract][Full Text] [Related]
18. Opioid receptor binding characteristics and structure-activity studies of novel tetrapeptides in the TIPP (Tyr-Tic-Phe-Phe) series.
Ioja E; Tóth G; Benyhe S; Tourwe D; Péter A; Tömböly C; Borsodi A
Neurosignals; 2005; 14(6):317-28. PubMed ID: 16772734
[TBL] [Abstract][Full Text] [Related]
19. The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.
Patkar KA; Murray TF; Aldrich JV
J Med Chem; 2009 Nov; 52(21):6814-21. PubMed ID: 19807094
[TBL] [Abstract][Full Text] [Related]
20. Superpotent [Dmt¹] dermorphin tetrapeptides containing the 4-aminotetrahydro-2-benzazepin-3-one scaffold with mixed μ/δ opioid receptor agonistic properties.
Vandormael B; Fourla DD; Gramowski-Voss A; Kosson P; Weiss DG; Schröder OH; Lipkowski A; Georgoussi Z; Tourwé D
J Med Chem; 2011 Nov; 54(22):7848-59. PubMed ID: 21978284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
